Παρακολούθηση
Tristan Maurer
Tristan Maurer
VP, Translational M&S, Medicine Design, Pfizer
Η διεύθυνση ηλεκτρονικού ταχυδρομείου έχει επαληθευτεί στον τομέα pfizer.com
Τίτλος
Παρατίθεται από
Παρατίθεται από
Έτος
Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery
J Cory Kalvass, TS Maurer
Biopharmaceutics & drug disposition 23 (8), 327-338, 2002
4802002
Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches
NA Hosea, WT Collard, S Cole, TS Maurer, RX Fang, H Jones, SM Kakar, ...
The Journal of Clinical Pharmacology 49 (5), 513-533, 2009
3112009
Volume of distribution in drug design: miniperspective
DA Smith, K Beaumont, TS Maurer, L Di
Journal of medicinal chemistry 58 (15), 5691-5698, 2015
2772015
Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and …
AS Kalgutkar, RS Obach, TS Maurer
Current drug metabolism 8 (5), 407-447, 2007
2772007
Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios
JC Kalvass, TS Maurer, GM Pollack
Drug metabolism and disposition 35 (4), 660-666, 2007
2682007
Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice
TS Maurer, DB DeBartolo, DA Tess, DO Scott
Drug metabolism and disposition 33 (1), 175-181, 2005
2532005
A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro
OA Fahmi, TS Maurer, M Kish, E Cardenas, S Boldt, D Nettleton
Drug Metabolism and Disposition 36 (8), 1698-1708, 2008
2232008
Relevance of half-life in drug design: Miniperspective
DA Smith, K Beaumont, TS Maurer, L Di
Journal of medicinal chemistry 61 (10), 4273-4282, 2017
1652017
Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction
SL Ripp, JB Mills, OA Fahmi, KA Trevena, JL Liras, TS Maurer, ...
Drug Metabolism and disposition 34 (10), 1742-1748, 2006
1562006
Clearance in drug design: miniperspective
DA Smith, K Beaumont, TS Maurer, L Di
Journal of Medicinal Chemistry 62 (5), 2245-2255, 2018
1462018
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo [3.2. 1] octane class of sodium-dependent glucose cotransporter 2 inhibitors
V Mascitti, TS Maurer, RP Robinson, J Bian, CM Boustany-Kari, T Brandt, ...
Journal of medicinal chemistry 54 (8), 2952-2960, 2011
1382011
PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti–glomerular basement membrane glomerulonephritis
W Zheng, R Warner, R Ruggeri, C Su, C Cortes, A Skoura, J Ward, K Ahn, ...
Journal of Pharmacology and Experimental Therapeutics 353 (2), 288-298, 2015
962015
Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data
JC Kalvass, DA Tess, C Giragossian, MC Linhares, TS Maurer
Drug metabolism and disposition 29 (10), 1332-1336, 2001
752001
A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling
R Li, HA Barton, PD Yates, A Ghosh, AC Wolford, KA Riccardi, TS Maurer
Journal of pharmacokinetics and pharmacodynamics 41, 197-209, 2014
732014
In silico modeling of nonspecific binding to human liver microsomes
H Gao, L Yao, HW Mathieu, Y Zhang, TS Maurer, MD Troutman, DO Scott, ...
Drug metabolism and disposition 36 (10), 2130-2135, 2008
732008
Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development
I Loryan, A Reichel, B Feng, C Bundgaard, C Shaffer, C Kalvass, ...
Pharmaceutical research 39 (7), 1321-1341, 2022
702022
Rapid Method to Determine Intracellular Drug Concentrations in Cellular Uptake Assays: Application to Metformin in OCT1-transfected HEK Cells
HC Chien, AA Zur, TS Maurer, SW Yee, J Tolsma, P Jasper, DO Scott, ...
Drug Metabolism & Disposition 44 (3), 356-364, 2016
682016
Impact of recovery on fraction unbound using equilibrium dialysis
L Di, JP Umland, PE Trapa, TS Maurer
Journal of pharmaceutical sciences 101 (3), 1327-1335, 2012
662012
Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl) pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation
AS Kalgutkar, DK Dalvie, J Aubrecht, EB Smith, SL Coffing, JR Cheung, ...
Drug metabolism and disposition 35 (6), 848-858, 2007
652007
Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based …
RB Ruggeri, L Buckbinder, SW Bagley, PA Carpino, EL Conn, ...
Journal of medicinal chemistry 58 (21), 8513-8528, 2015
612015
Δεν είναι δυνατή η εκτέλεση της ενέργειας από το σύστημα αυτή τη στιγμή. Προσπαθήστε ξανά αργότερα.
Άρθρα 1–20